MAR 02, 2021 5:00 AM PST

Another Trick up Tumors' Sleeves Exposed

WRITTEN BY: Tara Fernandez

Tumors have sneaky strategies for establishing themselves within healthy tissues, flourishing in plain sight of circulating immune cells. Understanding the molecular basis of how cancer does this can help researchers identify potential flaws in tumors' game, to improve the aim on therapeutic targets.

A team of immunologists at St. Jude Children's Research Hospital have uncovered one of these missing pieces in an article published in Nature. Here, they describe how tumors barricade themselves behind activated regulatory T cells (Tregs), creating a signal to other immune cells to put their weapons down. Tregs are specialized lymphocytes that balance immune-mediated inflammation and prevent the body from launching attacks on its own tissues.

The researchers found a mechanism for controlling Tregs unique to the tumor, making it an attractive therapeutic target. This pathway is an excellent starting point for creating drugs that selectively disarm tumor-associated Tregs, allowing immune cells to infiltrate and eliminate the malignant cells.

"There has certainly been a great deal of interest in targeting regulatory T cells for cancer therapy because they are central to keeping the immune system in check in tumors," said author of the paper, Hongbo Chi. "But the risk of such targeting is possibly inducing autoimmune disease because these T cells are crucial to balancing the body's immune response.”

According to Chi, the study’s findings are particularly exciting as tumors’ pathways to reprogram Tregs are entirely independent. "Thus, we believe there is the potential for inhibiting regulatory T-cell activation in tumors to unleash effective antitumor immune responses without triggering autoimmune toxicity."

Blocking T reg activation in tumors has the potential to improve the effectiveness of existing immunotherapies, which don’t always work well for all cancer patients.

"Anti-PD-1 therapy currently works in only about 20% of cancer patients, although when it works, the response is durable in those cases," explained Chi. "Many pediatric cancers are not responsive to anti-PD-1. Our experiments showed that blocking this lipid pathway had quite a remarkable effect in sensitizing mice to the therapy.”

Follow-up studies to map these tumor-Treg interactions in more detail are in the cards, said Chi. 

"While we still have a long research path ahead of us, these findings suggest that if we can develop drugs to control this context-specific regulatory T cell pathway in cancer patients, we can make them even more responsive to immunological checkpoint therapies."

 

 

Sources: St. Jude’s Children’s Hospital, Nature.


 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
JAN 13, 2021
Immunology
Antibodies Gain the Upper Hand Against Sly Tumors
JAN 13, 2021
Antibodies Gain the Upper Hand Against Sly Tumors
Tumors use ingenious approaches to stay just out of reach of immune cells on patrol and avoid detection. Indeed, cancer ...
FEB 03, 2021
Clinical & Molecular DX
New Panel of Arthritis Biomarkers Diagnoses Disease With 93.2% Accuracy
FEB 03, 2021
New Panel of Arthritis Biomarkers Diagnoses Disease With 93.2% Accuracy
Rheumatoid arthritis, or RA, is a painful and debilitating autoimmune disorder of the joints, particularly those of the ...
MAR 04, 2021
Immunology
Why Do We Need Two Shots of the COVID Vaccine?
MAR 04, 2021
Why Do We Need Two Shots of the COVID Vaccine?
Unlike social distancing, mask-wearing, and hand hygiene, vaccines are our best bet as a long-term solution to protectin ...
MAR 07, 2021
Genetics & Genomics
Tuberculosis Influenced the Human Genome
MAR 07, 2021
Tuberculosis Influenced the Human Genome
Throughout human history, our species has come into contact with both harmless and infectious microbes that have changed ...
MAR 23, 2021
Immunology
Assay Detects Antibodies in Asymptomatic COVID Carriers
MAR 23, 2021
Assay Detects Antibodies in Asymptomatic COVID Carriers
It is estimated that around one in five people infected with SARS-CoV-2 will not show any infection symptoms. Some of th ...
APR 01, 2021
Immunology
Tumor-Killing 101: Vaccine Trains Immune Cells to Keep Skin Cancer at Bay
APR 01, 2021
Tumor-Killing 101: Vaccine Trains Immune Cells to Keep Skin Cancer at Bay
Cancer researchers have developed a therapeutic vaccine for melanoma, a deadly form of skin cancer. Instead of protectin ...
Loading Comments...